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Abstract: Old world hantaviruses cause hemorrhagic fever with renal syndrome (HFRS) upon
zoonotic transmission to humans. In Europe, the Puumala virus (PUUV) is the main causative agent
of HFRS. Tula virus (TULV) is also widely distributed in Europe, but there is little knowledge about
the pathogenicity of TULV for humans, as reported cases are rare. We studied the replication of TULV
in different cell types in comparison to the pathogenic PUUV and analyzed differences in stimulation
of innate immunity. While both viruses replicated to a similar extent in interferon (IFN)-deficient
Vero E6 cells, TULV replication in human lung epithelial (A549) cells was slower and less efficient
when compared to PUUV. In contrast to PUUV, no replication of TULV could be detected in human
microvascular endothelial cells and in macrophages. While a strong innate immune response towards
PUUV infection was evident at 48 h post infection, TULV infection triggered only a weak IFN response
late after infection of A549 cells. Using appropriate in vitro cell culture models for the orthohantavirus
infection, we could demonstrate major differences in host cell tropism, replication kinetics, and innate
immune induction between pathogenic PUUV and the presumably non- or low-pathogenic TULV
that are not observed in Vero E6 cells and may contribute to differences in virulence.
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1. Introduction
Hantaviruses are three segmented negative-stranded RNA viruses which are harbored by small
mammals. They form the genus Orthohantavirus within the Hantaviridae family of the order Bunyavirales.
Upon zoonotic transmission to humans via aerosols, they cause a disease known as hemorrhagic fever
with renal syndrome (HFRS) in the old world and hantavirus cardiopulmonary syndrome (HCPS) in the
new world [1]. Hantavirus-associated diseases in Europe are mainly caused by infections with Puumala
virus (PUUV) carried by Myodes voles and to a lesser extent by Dobrava-Belgrade virus (DOBV) carried
by different Apodemus species [2]. While PUUV causes mainly a mild form of HFRS, also known
as nephropathia epidemica [3], DOBV infections tend to be more severe [2,4]. A third hantavirus,
Tula virus (TULV), is carried by Microtus voles which are widely distributed in Europe [2,5–7]. TULV
infection in humans has been serologically documented in blood donors in the Czech Republic [8]
and in German forestry workers, a potential risk group for hantavirus infections [9]. There is little
knowledge about the pathogenicity of TULV, as reported cases of disease caused by TULV infection
are rare, without any fatalities known so far. One HFRS patient from Germany had TULV-specific
neutralizing antibodies [10]. In addition, TULV RNA was detected in EDTA blood of an acutely
infected, immunocompromised patient in the Czech Republic [11]. Furthermore, TULV infection was
detected in a hospitalized patient in France in 2015 [12]. However, as often no differentiation is made
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between infections by TULV or the closely related PUUV, more cases of human TULV infections may
exist which are misdiagnosed as PUUV infections [13].
In human hantavirus infections, a dysregulation of endothelial cell functions—either caused
by the infection itself or by an excessive immune response towards the infection—is thought to be
the cause of the hantavirus-induced pathologies [14,15]. However, the determinants for the diverse
degrees of hantavirus pathogenicity observed in humans are still unclear. Differences in receptor
usage may play a role, as pathogenic hantaviruses like PUUV enter cells via β3 integrins while
low-pathogenic hantaviruses like TULV utilize β1 integrins for entry, and subversion of the β3 integrin
signaling pathway is thought to compromise vascular integrity [15]. Furthermore, differences in entry
mechanisms or modulation of the host cell machinery may in turn affect viral replication kinetics
and thereby determine hantavirus virulence [15,16]. Differential regulation of the innate immune
response is also considered as one of the pathogenicity determinants. Like all viruses, hantaviruses
need to prevent early induction of the cellular antiviral interferon (IFN) response in order to replicate
successfully in human cells [17–19]. Several reports have shown that hantavirus replication is sensitive
to IFN and that IFN induction by hantavirus infection differs between viral species (reviewed in [20]).
The non-pathogenic prospect hill virus (PHV) has been shown to differ from other hantaviruses in its
inability to restrict early type I IFN responses, rendering it unable to replicate in endothelial cells [21,22].
However, while early activation of innate immune responses limits viral replication and thereby
the development of hantavirus pathology, a delayed and subsequently exaggerated innate immune
response towards uncontrolled viral replication most likely contributes to pathogenicity [16,23–26].
This suggests that the ability of hantaviruses to modulate innate immunity actually relates to their
various degrees of pathogenicity.
In this study, we compared the replication efficiency of the pathogenic PUUV and the non- or
low-pathogenic TULV in different cell types and analyzed differences in immune stimulation between
these viruses. In human infections, hantaviruses mainly infect endothelial cells and macrophages.
As an in vitro model for human endothelial cells, the well-characterized cell line HMEC-1 was
used [27], which closely resembles microvascular endothelial cells in regard to many phenotypic
characteristics [28,29]. Infection of macrophages was studied in PMA-differentiated THP-1 cells
in comparison to peripheral blood mononuclear cell (PBMC)-derived macrophages. Furthermore,
infection of lung epithelial cells was studied, which may in vivo represent the first cells to be in contact
with the virus after inhalation of hantavirus particles. In this study, we used A549 lung epithelial
cells, which have been widely used as an in vitro model system for hantavirus infections, including
gene expression profiling [30–35]. Our results show that PUUV replicates efficiently in all tested cell
types, whereas TULV replication was considerably weaker or even undetectable in all cell types except
IFN-deficient Vero E6 cells. While the rapid PUUV replication induced a strong IFN response as early
as 48 h post infection (p.i.), no stimulation of innate immune responses by TULV was monitored during
the first six days post infection. In case these differences in host cell tropism, replication kinetics, and
innate immune stimulation observed in vitro are also present in the more complex in vivo situation,
these may contribute to the higher pathogenicity of PUUV in comparison to TULV in the human host.
2. Materials and Methods
2.1. Virus Cultivation
PUUV (strain Kazan) [36] and TULV (strain Moravia-5302Ma-94) [8] were grown on Vero E6
cells (American Type Culture Collection (ATCC), Manassas, VA, USA; CRL 1586) in T175 cell culture
flasks under standard cell culture conditions (Dulbecco’s Modified Eagle’s Medium (DMEM), 5% fetal
calf serum (FCS), 37 ◦C). Cells were infected in 2 mL of DMEM containing 1% FCS for 2 h using a
multiplicity of infection (MoI) of 0.005. Subsequently, 28 mL of DMEM medium containing 5% FCS
were added and the cells were incubated for 7 d. At 7 d p.i. 20 mL of the virus containing cell culture
supernatant were harvested, followed by a centrifugation step to remove cellular debris (1000× g, 5 min,
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4 ◦C). The cells were disrupted in the remaining 10 mL of medium by three consecutive freeze/thaw
cycles (−20 ◦C) followed by sonication (Bioruptor Plus, Diagenode SA, Seraing, Belgium; 3 × 30 s, 4 ◦C,
high intensity) and removal of cellular debris via centrifugation (1000× g, 5 min, 4 ◦C). Subsequently,
the virus containing supernatants were pooled and viral particles were enriched via sucrose cushion
ultracentrifugation (30% sucrose; 175,000× g, 1.5 h, 4 ◦C). Viral stocks were titrated by focus forming
unit (FFU) assay and stored in aliquots at −80 ◦C for further use. Stocks of comparable virus titers of
approximately 1 × 107 FFU/mL were used for infection experiments. All virus stocks were tested and
found to be negative for mycoplasma and SV5 contamination. Biosafety level 2 facilities were used for
virus cultivation and experimental infections.
2.2. Cell Lines
A549 human lung carcinoma epithelial cells (ATCC® CCL-185™), HMEC-1 human microvascular
endothelial cells (ATCC® CRL-3243), THP-1 human monocytic cells (ATCC® TIB-202™) and Vero E6
green monkey epithelial kidney cells (ATCC CRL-1586) were cultured under standard conditions in
24-well cell culture plates. A549 cells and Vero E6 cells were cultivated in DMEM containing 10% FCS
and 2 mM L-Glutamine. HMEC-1 cells were cultivated in MCDB131 medium containing 10% FCS,
10 mM L-Glutamine, 10 ng/mL epidermal growth factor (EGF) and 1 µg/mL Hydrocortisone. THP-1
cells were cultivated in RPMI medium containing 10% FCS and 2 mM L-Glutamine. For differentiation
into a macrophage-like phenotype, THP-1 cells were treated with phorbol 12-myristate 13-acetate
(PMA) at 100 ng/mL for 72 h.
2.3. Infection
Cells were infected with the described viruses at a MoI of 0.1 or 1.0 and the virus was adsorbed
for 1 h. Mock infections were performed using a culture medium free of virus. At the designated
time points, cell-free cell culture supernatants were harvested and used for total RNA extraction using
the QIAamp viral RNA mini kit (Qiagen, Hilden, Germany) and for titration of infectious viruses via
FFU assay. Adherent cells were washed in PBS and lysed in RIPA buffer (Thermo Fisher Scientific,
Waltham, MA, USA) for immunoblotting or in RA1 buffer (Macherey-Nagel, Düren, Germany) for
RNA-extraction using the NucleoSpin RNA Kit (Macherey-Nagel).
2.4. Focus Forming Unit Assay
Quantification of infectious viruses in cell culture supernatants was done by means of FFU assay,
as described previously [35]. Briefly, Vero E6 cells were seeded in black optical-bottom 96-well plates.
Confluent monolayers were incubated with decadal dilutions of samples. Viruses were allowed to
adhere for 1 h, before the cells were overlaid with medium containing 3.2% carboxymethyl cellulose.
At 7 d p.i. the cells were washed in PBS, fixed with ice-cold methanol, and foci of infected cells were
detected using anti-hantavirus nucleocapsid antibody (ab34757, Abcam, Cambridge, UK) and Alexa
Fluor® 488 conjugated secondary antibody (Anti-mouse IgG (H + L), F(ab’)2 Fragment Alexa Fluor®
488 Conjugate, Cell Signaling Technology, Danvers, MA, USA). Foci of infected cells were counted
using a fluorescence microscope. All samples were tested in quadruplicate.
2.5. Quantitative Reverse Transcription PCR
The isolated RNA from cell culture supernatants was used as template in one-step quantitative
reverse transcription (qRT) PCR analysis using the Ambion AgPath-ID Kit (Thermo Fisher Scientific).
Viral nucleic acids in the cell culture supernatant were quantified using PUUV- or TULV-specific qPCR
assays [37]. Isolated RNA from cultivated cells was converted to cDNA using SuperScript IV reverse
transcriptase (Thermo Fisher Scientific) and random primer mix (New England Biolabs, Ipswich, MA,
USA). Analysis of host cell gene expression was performed using commercially available TaqMan®Gene
Expression Assays (Thermo Fisher Scientific; IFNB1 (Hs01077958_s1); IFNA1 (Hs04189288_g1); IFNAR1
(Hs01066116_m1); IFNAR2 (Hs01022059_m1); IFNE (Hs00703565_s1); IFNK (Hs00737883_m1); IFNW1
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(Hs00958789_s1); IFNL1 (Hs00601677_g1); IFNL2 (Hs00820125_g1); IFNG (Hs00989291_m1). MYC gene
expression was measured as a reference gene for ∆cT normalization, as described previously [38]. Each
PCR setup included no-template controls.
2.6. Immunoblotting
Expression of the hantavirus nucleocapsid protein and of cellular proteins was analyzed via
immunoblotting of whole cell lysates of infected cells. The hantavirus nucleocapsid protein was detected
using an anti-hantavirus nucleocapsid protein antibody (Abcam; ab34757). Cellular Phospho-STAT1
was detected using Phospho-Stat1 (Tyr701) (D4A7). Rabbit mAb, PKR (EIF2AK2) was detected using
the PKR (D7F7). Rabbit mAb, MxA (MX1) was detected using the MX1 (D3W7I) Rabbit mAb and
b-Actin, respectively, GAPDH were detected using β-Actin Antibody and GAPDH (D16H11) XP®
Rabbit mAb (all: Cell Signaling Technology).
3. Results
3.1. Puumala Virus Replicates More Efficiently Than Tula Virus in IFN-Competent Cell Types
In this study, we compared the replication of TULV and PUUV in human epithelial and endothelial
cells, as well as in cells of the monocyte–macrophage lineage. The cells were infected with a multiplicity
of infection (MoI) of 0.1 and viral RNA concentrations in the cell culture supernatants were quantified
via qRT-PCR at 0 h to 6 d p.i. (Figure 1). All experiments were performed in duplicate using RNA
samples from two independently infected cell cultures for each analysis.
As expected, both TULV and PUUV replicated successfully in the IFN-deficient Vero E6 cells.
While PUUV replicated more rapidly in the beginning, at 6 d p.i. viral RNA quantities were comparable
in the supernatants of TULV- and PUUV-infected Vero E6 cells. This was not the case in the lung
epithelial A549 cells, where again a rapid amplification of PUUV RNA could be observed in the cell
culture supernatants during the first 2 d p.i., which increased even more until 6 d post infection. In
contrast, only a slight increase in TULV RNA concentrations could be observed until 6 d post infection.
In the microvascular endothelial HMEC-1 cells, PUUV showed RNA amplification kinetics similar
to those in the A549 cells, albeit the replication was overall less efficient. In TULV-infected HMEC-1
cells, no replication of viral RNAs could be observed during 6 d post infection. In the macrophage-like
PMA-differentiated THP-1 cells, a rapid increase of PUUV RNA occurred in the supernatants during
the first 3 d post infection. In contrast, viral RNA concentrations in the supernatants of TULV-infected
THP-1/PMA cells increased only slightly between 3 d and 6 d post infection.
The RNA amplification kinetics in the selected endothelial and macrophage-like cell lines closely
resembled those observed in primary cells (Figure S1). Similarly to the HMEC-1 and THP-1/PMA
cells, amplification of PUUV RNA could also be observed in the supernatants of primary glomerular
microvascular endothelial cells (HGMEC) and granulocyte-macrophage colony-stimulating factor
(GM-CSF) polarized PBMC-derived M1 macrophages, whereas no replication of TULV was detectable
in these cells. In contrast, in macrophage colony-stimulating factor (M-CSF) polarized PBMC-derived
M2 macrophages, both viruses failed to replicate, as no increase of viral RNA in the cell culture
supernatant was detectable during 6 d post infection.










Figure 1. Quantification of viral RNA. The amplification of viral RNAs in supernatants of Puumala 
virus (PUUV)- and Tula virus (TULV)-infected a) Vero E6, b) A549, c) HMEC-1, and d) THP-1/PMA 
cells was quantified by means of qRT-PCR analysis of viral RNA copies in cell-free cell culture 
supernatants. Cells were infected with a multiplicity of infection (MoI) = 0.1 and viral RNA copies 
were quantified at 0 h, 1 d, 2 d, 3 d, and 6 d post infection. 
As an additional marker of viral replication, we analyzed the expression of the viral 
nucleocapsid (N) protein in cell lysates via immunoblotting (Figure 2). Again, a clear increase in N 
protein expression could be observed in the PUUV-infected cells, starting from 2 d p.i. in the Vero 
E6, A549, and HMEC-1 cells, or even 1 d p.i. in the THP-1/PMA cells. In contrast, a strong expression 
of the TULV N protein was only detectable in the Vero E6 cells at 6 d post infection. 
The N protein expression in the cell lines was very similar to primary cells, proving the 
suitability of the selected cell lines as in vitro model systems of endothelial cells and macrophages. In 
the PUUV-infected M1 and M2 polarized macrophages, viral N protein expression increased rapidly 
during the first 2 d p.i., followed by a decrease between 3 d and 6 d p.i. (Figure S2). In the 
TULV-infected M1 and M2 polarized macrophages, no N expression was observable after the initial 
infection (0 h p.i.). In the HGMECs, only PUUV infection led to an accumulation of N protein from 2 
d to 6 d post infection (Figure S3). 
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To verify that the increasing amounts of viral RNA in the supernatants and of viral N protein in
the lysates of infected cells correlate with successful viral replication and the production and release of
viral progeny, we quantified the concentrations of infectious virus particles in cell culture supernatants
at 6 d p.i. via FFU assay (Figure 3). Again, we could prove that both viruses replicate efficiently in the
Vero E6 cells, in which TULV titers even excelled those of PUUV. In the A549 cells, PUUV replicated to
comparable titers as in the Vero E6 cells. However, TULV replicated less efficiently, reaching titers
10-fold lower than PUUV at 6 d p.i. and more than 40-fold lower when compared to the TULV titers in
the Vero E6 cells. In the supernatants of THP-1/PMA and HMEC-1 cells, almost no infectious TULV
particles were detectable at 6 d p.i., whereas PUUV replicated successfully, albeit PUUV titers were
approximately 100-fold lower compared to the A549 and Vero E6 cells.
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In combination, our results show clear differences in the kinetics of viral replication between
pathogenic PUUV and the non- or low-pathogenic TULV. Both viruses efficiently infected IFN-deficient
Vero E6 cells and replicated to comparable titers. However, a faster onset of viral RNA amplification
and a more pronounced accumulation of viral N protein were observed in the PUUV-infected cells.
This became even more evident in the A549 lung epithelial cells, where TULV replication was less
vigorous when compared to PUUV, leading to significantly reduced titers at 6 d post infection. The
endothelial HMEC-1 and the macrophage-like THP-1/PMA cells supported PUUV replication less well
than A549 or Vero E6 cells. Still, a rapid onset of viral N protein expression and efficient production and
release of viral progeny could be detected, while TULV replication was very weak or even undetectable
in these cells.




Figure 2. Viral nucleocaspid protein expression in PUUV- and TULV-infected cells. The expression 
of the viral nucleocapsid (N) protein was analyzed via immunoblotting in lysates of PUUV- or 
TULV-infected Vero E6, A549, HMEC-1, and THP-1/PMA cells. Cells were infected with a MoI = 0.1 
and N expression was detected at 0 h, 1 d, 2 d, 3 d, and 6 d post infection. Detection of β-Actin served 
as loading control. 
To verify that the increasing amounts of viral RNA in the supernatants and of viral N protein in 
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Figure 2. Viral nucleocaspid protein expression in PUUV- and TULV-infected cells. The expression of the
viral nucleocapsid (N) protein was analyzed via immunoblotting in lysates of PUUV- or TULV-infected
Vero E6, A549, HMEC-1, and THP-1/PMA cells. Cells were infected with a MoI = 0.1 and N expression
was detected at 0 h, 1 d, 2 d, 3 d, and 6 d post infection. Detection of β-Actin served as loading control.
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In combination, our results show clear differences in the kinetics of viral replication between 
pathogenic PUUV and the non- or low-pathogenic TULV. Both viruses efficiently infected 
IFN-deficient Vero E6 cells and replicated to comparable titers. However, a faster onset of viral RNA 
amplification and a more pronounced accumulation of viral N protein were observed in the 
PUUV-infected cells. This became even more evident in the A549 lung epithelial cells, where TULV 
replication was less vigorous when compared to PUUV, leading to significantly reduced titers at 6 d 
post infection. The endothelial HMEC-1 and the macrophage-like THP-1/PMA cells supported 
PUUV replication less well than A549 or Vero E6 cells. Still, a rapid onset of viral N protein 
Figure 3. Progeny virus titers at 6 d .i. with PUUV or TULV. e release of i fectio s ir ses fro
P - r -i fected (a) er 6, ( ) 549, (c) HMEC-1, and (d) THP-1/PMA cells were quantified
by focus f r ing nit ( F ) assay. ells ere i f ct it I 0.1 and i fectious viruses ere
a tifi i ll-f ll lt t t t t i f ti .
3.2. PUUV Infection Induces IFN-β and IFN-λ Gene Expression
To further investigate the reasons underlying the inefficient TULV replication in all cells except
IFN-deficient Vero E6 cells, we analyzed the IFN response towards PUUV and TULV infection. To do
so, the expression of cellular IFN genes was quantified via qRT-PCR in TULV-, PUUV- or mock-infected
HMEC-1, and THP-1/PMA cells (MoI = 1.0) at 0 h to 48 h post infection.
Expression of IFN-α1 (IFNA1) was not detectable in the THP-1/PMA cells and only weakly in the
HMEC-1 cells, in which IFNA1 gene expression was comparable in infected vs. mock-infected cells
(data not shown). Likewise, expression of IFN-ε (IFNE) was weakly detectable in HMEC-1 cells but
showed a comparable progression in infected and mock-infected cells. Expression of IFN-ω (IFNW1),
IFN-κ (IFNK) and IFN-γ (IFNG) was not detectable at all (data not shown). Expression of the type I
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IFN receptors IFNAR1 and IFNAR2 was detected in the HMEC-1 cells but expression was not altered
by PUUV or TULV infection (data not shown).
However, a strong induction of IFN-β (IFNB1) expression could be observed at 24 h and 48 h
following PUUV infection of HMEC-1 and THP-1/PMA cells (Figure 4). Similarly, IFN-λ (IFNL1 and
IFNL2) expression increased at 48 h post PUUV infection, being mostly non-detectable in TULV- or
mock-infected samples or at earlier time points (Figure S4).
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Figure 4. IFNB1 gene expression in response to infection. Expression of the IFNB1 gene was quantified
in response to PUUV or TULV infection of (a) HMEC-1 or (b) THP-1 cells via qRT-PCR and normalized
to the expression of the cellular MYC gene. Cells were infected using a MoI of 1.0 and lysed at the
indicated time points. No IFNB1 expression was detectable at 24 h p.i. in non-infected or TULV-infected
THP-1/PMA cells.
3.3. PUUV but Not TULV Infection Induces Phosphorylation of STAT1 and Interferon-stimulated Gene
Expression in Endothelial Cells and Monocytes/Macrophages
Subsequently, we analyzed the phosphorylation and activation of the IFN-responsive transcription
factor STAT1 and the expression of the antiviral IFN-induced dsRNA-activated protein kinase (PKR)
in lysates of PUUV- or TULV-infected HMEC-1 and THP-1/PMA cells via immunoblotting (Figure 5).
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In congruence with the stimulation of IFN gene expression, STAT1 phosphorylation was evident
starting from 48 h p.i. in the PUUV-infected cells. This correlated with an accumulation of the viral N
protein in PUUV-infected cells and also with a subsequent induction of IFN-induced PKR expression
at 3 d to 6 d post infection. No increase in STAT1 phosphorylation or PKR expression could be
observed until 6 d following TULV infection of HMEC-1 or THP-1/PMA cells and no viral N protein
was detectable in TULV-infected cells after the initial infection (0 h p.i.).
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normalized to the expression of the cellular MYC gene. Cells were infected using a MoI of 1.0 and 
lysed at the indicated time points. No IFNB1 expression was detectable at 24 h p.i. in non-infected or 
TULV-infected THP-1/PMA cells. 
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kinase (PKR) in lysates of PUUV- or TULV-infected HMEC-1 and THP-1/PMA cells via 
immunoblotting (Figure 5). In congruence with the stimulation of IFN gene expression, STAT1 
phosphorylation was evident starting from 48 h p.i. in the PUUV-infected cells. This correlated with 
an accumulation of the viral N protein in PUUV-infected cells and also with a subsequent induction 
of IFN-induced PKR expression at 3 d to 6 d post infection. No increase in STAT1 phosphorylation or 
PKR expression could be observed until 6 d following TULV infection of HMEC-1 or THP-1/PMA 
cells and no viral N protein was detectable in TULV-infected cells after the initial infection (0 h p.i.). 
 
 Figure 5. Interferon-stimulated protein expression in PUUV- and TULV-infected cells. The
phosphorylation of STAT1 (Tyr701) and the expression of the cellular antiviral dsRNA-activated
protein kinase PKR (EIF2AK2) was analyzed in lysates of PUUV- or TULV-infected HMEC-1 and
THP-1/PMA cells. Expression of the viral nucleocapsid (N) protein was detected to monitor infection
and cellular β-Actin served as loading control. Cells were infected with a MoI of 0.1 and protein
expression was detected at 0 h, 1 d, 2 d, 3 d, and 6 d p.i. or in non-infected cells.
These data indicate that TULV replication is most likely not hampered by an early induction of an
IFN response in the HMEC-1 and THP-1/PMA cells. Instead, our data shows that the more vigorous
PUUV infection of these cells induces a much stronger IFN response than the weak or abortive TULV
infection. This is also supported by the detection of a strong MxA (MX1) expression in PUUV- but not
in TULV-infected HGMECs (Figure S3).
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3.4. TULV Replication Induces Only a Weak IFN Response in Permissive A549 Cells in Comparison to PUUV
TULV did not induce a detectable IFN response in the HMEC-1 and THP-1/PMA cells. However,
productive replication of TULV was also not detectable in these cells. Therefore, we aimed to analyze if
successful TULV replication in A549 cells may induce an IFN response comparable to that triggered by
the actively replicating PUUV. To compensate for the slower replication of TULV in the A549 cells, we
analyzed the expression of the IFN-stimulated antiviral MxA (MX1) protein following TULV or PUUV
infection with a MoI of either 0.1 or 1.0 at 7 d and 14 d p.i. (Figure 6). In the cells infected with TULV at
a MoI of 0.1, even after 14 d of infection, almost no N protein expression was detectable. In contrast to
mock-infected cells, MX1 expression was weakly detectable at 14 d post TULV infection. MX1 and N
expression were more pronounced following TULV infection at a MoI of 1.0, however both were still
considerably weaker than in the PUUV-infected cells.
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Figure 6. IFN-stimulated MX1 expression in PUUV- and TULV-infected cells. The expression of the
cellular IFN-stimulated protein MX1 was analyzed in lysates of PUUV- or TULV-infected A549 cells.
Expression of the viral nucleocapsid (N) protein was detected to monitor infection and cellular GAPDH
served as loading control. Cells were infected with a MoI of 0.1 or 1.0 and protein expression was
detected at 7 d or 14 d post infection.
We conclude that active replication of TULV induces an IFN response in infected cells. However,
in comparison to PUUV, TULV replication is much less efficient in most of the tested cell types,
as can be seen by the weaker expression of viral N protein and viral RNAs. Most likely, this reduced
accumulation of virus-derived immunostimulatory molecular patterns results in the weaker IFN
response towards TULV in contrast to PUUV infection.
4. Discussion
While many hantaviruses are pathogenic to humans, some—like PHV—are considered
non-pathogenic [20]. PUUV is the most important cause of HFRS in Europe, causing around
10,000 infections per year [2]. In contrast, the pathogenicity of the widely distributed TULV is
still unclear. Although serological data shows that human infections occur, only a few reports of
disease caused by TULV exist [8–12]. The mechanisms underlying the various degrees of hantavirus
pathogenicity are still unknown. However, solid evidence exists that pathogenic and non-pathogenic
hantaviruses differ in their interaction with the host immune system and both innate and adaptive
immune responses have been shown to contribute to the hantavirus-associated disease [17,18,20,39].
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The initial sensing of a hantavirus infection by the innate immune system is mediated through
germ-line encoded pattern recognition receptors (PRRs). Recognition of hantaviral RNA species
via endosomal Toll-like receptor-3 (TLR-3) [40] and the cytoplasmic retinoic acid-inducible gene I
(RIG-I) RNA helicase [30] induces the activation of signaling cascades that lead to the production and
secretion of IFNs, which in turn induce the expression of IFN-stimulated genes (ISGs) like antiviral
MxA (MX1) [18]. Three types of IFN have been described to date (I, II, and III), which are categorized
by the type of receptors they use for signaling. The type I IFN family includes IFN-α, IFN-β, IFN-ε,
IFN-κ, IFN-τ, and IFN-ω, and signal via the IFNAR1 and IFNAR2 receptor chains. IFN-γ is the sole
member of the type II family, signaling through IFNGR1 and IFNGR2. Type III IFNs are the latest
addition to the IFN family. The four members (IFN-λ1–IFN-λ4) signal via a receptor complex involving
IL-10R2 and IL-28Ra subunits (reviewed in [41]). Type I and type III IFNs are expressed following
detection of pathogens by PRRs, and the signaling pathways that induce type I and type III IFNs
largely overlap, although a differential requirement for IRFs and NF-κB in the induction of type I and
type III IFNs has been described (reviewed in [42]). The expression of different IFN types is tissue
dependent and, in our hands, only IFN-β and IFN-λ were induced by hantavirus infection in the
studied cell types. Early activation of the IFN response during hantavirus infection is sufficient to block
viral replication. Therefore, for hantaviruses to be pathogenic, they need to prevent or at least delay
early IFN induction [17–19]. A delayed induction of an excessive innate immune response however is
unable to control the infection and is believed to contribute to pathogenesis [26,43–45].
In this study, we investigated and compared the replication of the pathogenic PUUV and
presumably non- or low-pathogenic TULV in vitro in different cell types and analyzed the induction
of innate immune responses by both viruses. PUUV has been previously reported to have a wide
in vitro host cell range, replicating successfully not only in IFN-deficient Vero cells, but also in human
umbilical vein endothelial cells (HUVECs) [46,47], in primary human monocytes/macrophages and
PMA-differentiated THP-1 cells [48], as well as in primary human kidney cells [49] and several
established cell lines [50]. However, PUUV replication in human cells is usually less efficient than in
cells of its natural host or IFN-deficient Vero E6 cells [50].
TULV has been reported to replicate efficiently in IFN-deficient Vero E6 cells [8,51], also it has been
shown to induce apoptosis in these cells [52]. Furthermore, like PHV, and in contrast to the Hantaan
virus (HTNV), TULV has been previously shown to be unable to replicate efficiently in the human
megakaryocytic HEL cell line [53]. There are conflicting results concerning the capability of TULV
to replicate in HUVECs. One study shows inefficient TULV replication in HUVECs in comparison
to HTNV, which was accompanied by weaker IFN-β induction, most likely due to the less efficient
replication [54]. In contrast, results from another group show successful replication of TULV in
HUVECs, which was accompanied by a strong induction of the ISGs MxA (MX1) and ISG56 (IFIT1) [55].
In our hands, TULV was not able to replicate efficiently in endothelial cells. This was independent
of the TULV strain, as similar results were observed for the TULV strains Moravia-5302Ma-94 and
Lodz (Figure S5). Similarly, no efficient replication of TULV was observed in the macrophage-like
PMA-treated THP-1 cells, while only weak replication of TULV was observed in A549 cells. Inefficient
replication of TULV in A549 cells has also been reported by Shim et al. [33], who also show that
non-pathogenic hantaviruses are less resistant to the antiviral activities induced by IFN-β.
The inefficient replication of TULV is in stark contrast to PUUV, which replicated productively in
all tested cell types, albeit replication was strongest in the IFN-deficient Vero E6 cells. In all tested
cell types, PUUV infection resulted in a strong IFN response at approximately 48 h p.i., which has
been described by previous reports as well [30,43,56] (also reviewed in [18–20]). Receptor binding of
type I or III IFNs results in phosphorylation of STAT1, which induces STAT1 dimerization, nuclear
translocation, and IFN-stimulated response elements (ISRE)-dependent gene expression of ISGs [57].
Consistent with this, we could show that induction of IFN-β and IFN-λ expression in PUUV-infected
cells was accompanied by subsequent phosphorylation of STAT1 and increased expression of PKR and
MX1. This IFN response towards PUUV infection was dependent on active viral replication and was
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not caused by residual IFNs in viral stock preparations, which was verified by infection experiments
using UV-irradiated PUUV stocks or stocks depleted of infectious viruses via exclusion filtration
(300 kDa) [58]. Neither infection with PUUV stocks inactivated via UV-irradiation nor treatment with
PUUV stocks depleted of infectious viral particles resulted in a detectable IFN response (Figure S6).
The inability of a non-pathogenic hantavirus to replicate in human endothelial cells has been
described before in the case of PHV. The non-pathogenic PHV has been shown to be unable to replicate
in HUVECs, which is caused by an early IFN induction triggered by PHV infection [21]. In contrast
to this, we did not observe a strong early IFN response towards TULV infection of HMEC-1 and
THP-1/PMA cells. This is in agreement with previous reports showing that TULV—in contrast to
PHV—is able to inhibit early IFN induction through its Gn protein cytoplasmic tail (Gn-T), which
blocks RIG-I- and TBK1-directed transcription from ISREs and IFN-β promoters [55]. Furthermore,
TULV, like PUUV, encodes a functional non-structural NSs protein, which is believed to play a role
in IFN regulation [59,60]. In contrast to PUUV, TULV infection did also not induce a substantial IFN
response between 2 d and 6 d post infection. This non-detectable IFN induction may be explained by
the weak or even undetectable replication of TULV in comparison to PUUV. This is also supported
by the fact that both PUUV and TULV induce IFN-λ expression in Vero E6 cells (Figure S7), in which
both viruses replicate to similar titers. While being IFN-α/β incompetent [61], previous reports have
already described IFN-λ production by hantavirus-infected Vero E6 cells [34,62]. Furthermore, our
results indicate that the slower and less-efficient replication of TULV in A549 cells is also accompanied
by a much less severe induction of innate immune responses by TULV in comparison to PUUV in
these cells, supporting the notion that the more vigorous PUUV replication triggers the stronger IFN
response in these cells. These results are also in agreement with our previous data, showing that TULV
infection of A549 cells is less IFN-stimulatory than infection with pathogenic DOBV [35].
Except for differences in the viruses ability to modulate the innate immune response towards
infection, the more efficient replication of PUUV compared to TULV may also be explained by different
entry mechanisms, as PUUV uses αVβ3 and TULV α5β1 integrins for entry (reviewed in [20]). However,
we found the expression ofβ1 integrins to be comparable in THP-1/PMA, A549, and HMEC-1 cells—and
even slightly stronger than in Vero E6 cells—and integrin α5 to be strongly expressed in the THP-1/PMA
and HMEC-1 cells (Figure S8). Therefore, a lack of receptor expression is most likely not the cause of
the inefficient TULV replication in THP-1/PMA and HMEC-1 cells.
Of course it has to be considered that phenotypic differences observed in vitro may at least in part
be caused by accumulation of natural mutations, acquired during propagation in cell culture, as it has
been shown for different substrains of PUUV [63]. To exclude this possibility, we also analyzed the
replication of the TULV strain Lodz and PUUV strain CG1820 in HMEC-1 cells. While PUUV CG1820
replicated in HMEC-1 cells, TULV Lodz—like TULV Moravia-5302Ma-94—failed to replicate efficiently
within 6 d post infection. Furthermore, while PUUV CG1820 strongly induced an IFN response upon
infection of A549 cells, this was not the case following infection with TULV Lodz, as with TULV
Moravia-5302Ma-94 (Figures S5 and S9).
In conclusion, we could show major differences between the pathogenic PUUV and the presumably
non- or low-pathogenic TULV regarding their in vitro replication efficiency in different cell types. PUUV
replicates successfully in all tested cell types except for M2-like polarized macrophages. In contrast,
TULV showed efficient replication only in IFN-deficient Vero E6 cells, while TULV replication in
IFN-competent A549 lung epithelial cells was considerably weaker and no viral replication could be
detected in the endothelial HMEC-1 or in the macrophage-like cells. Productive PUUV replication
was characterized by an accumulation of viral N protein in infected cells. Strong expression of the
viral N protein was detectable approximately 48 h p.i., which correlated with the onset of a strong IFN
response towards PUUV infection. Following TULV infection, a comparably weaker expression of
the N protein was observed, even in the permissive Vero E6 and A549 cells. This correlated with a
slower viral replication and also a more delayed and weaker IFN response towards TULV infection.
Our results underline the complexity of the interplay between virus and innate immune responses.
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As the virulence of viruses is often determined by replication kinetics, the less efficient replication of
TULV in endothelial cells and macrophages may be one of the factors explaining the presumably lower
pathogenicity of TULV compared to PUUV, at least if these in vitro observations are reflective of the
more complex in vivo situation. However, the differences in virus host cell interactions that determine
the less efficient TULV replication need further investigation, as this could not be explained by an early
IFN response towards TULV infection or a lack of expression of cellular α5β1 integrins required for
TULV entry. Moreover, further attempts have to be done to understand if the strong IFN response
caused by PUUV in vitro may possibly contribute to immunopathology in vivo or rather distinguishes
the moderately pathogenic PUUV from other highly pathogenic hantaviruses.
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